Lv6
2060 积分 2021-07-16 加入
EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47
16小时前
待确认
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
20天前
已完结
Deterministic reprogramming of neutrophils within tumors
1个月前
已完结
The next generation of immunotherapies for lung cancers
1个月前
已完结
Bispecific and multispecific antibodies in oncology: opportunities and challenges
1个月前
已完结
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
1个月前
已完结
The present and future of bispecific antibodies for cancer therapy
1个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
1个月前
已完结
GSTA1 conferred tolerance to osimertinib and provided strategies to overcome drug-tolerant persister in EGFR-mutant lung adenocarcinoma
1个月前
已完结
Eradicating Drug Tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T cellular therapy
3个月前
已完结
皖公网安备34019202002308
